{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-26-000007","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.657466+00:00","generated_at":"2026-05-15T19:40:58.593973+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Caribou Biosciences FY2025 net loss $148.1M; cash $142.8M funds into 2H 2027","bullets":["GAAP net loss FY2025 $148.1M ($1.59/sh) vs $149.1M ($1.65) prior year; non-GAAP loss $126.8M excluding $21.3M impairment.","Revenue FY2025 $11.2M (vs $10.0M in 2024); R&D expenses down to $109.4M due to workforce reduction and pipeline prioritization.","Cash, equivalents, marketable securities $142.8M at Dec 31, 2025, down from $249.4M; funding expected into 2H 2027; exploring options for pivotal trial.","Vispa-cel (CB-010) phase 1 data shows efficacy on par with autologous CAR-T; FDA engagement for pivotal trial design; longer follow-up expected 2026.","CB-011 dose expansion initiated for multiple myeloma; initial data expected in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-26-000007","json":"https://secwatch.observer/filing/0001619856-26-000007.json","markdown":"https://secwatch.observer/filing/0001619856-26-000007.md","text":"https://secwatch.observer/filing/0001619856-26-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985626000007/0001619856-26-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985626000007/crbu-20260305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:40:58.593973+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}